CMCaiyun Ma

Caiyun Ma

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Caiyun Ma has a total of 24 co-authors. Here are the top co-authors by number of shared publications:

  • Hebao Wen

    Anhui Engineering Research Center for Neural Regeneration Technology and Medical New Materials Bengbu Medical University Bengbu China

    2 shared publications
  • Liu Changqing

    Anhui Engineering Research Center for Neural Regeneration Technology and Medical New Materials Bengbu Medical University Bengbu China

    2 shared publications
  • Wu Huan

    West China School of Basic Medical Sciences and Forensic Medicine Sichuan University Chengdu China

    2 shared publications
  • Xiang Ge

    The Second Affiliated Hospital of Bengbu Medical University, Anhui, China

    2 shared publications
  • Yang Yuanyuan

    Anhui Engineering Research Center for Neural Regeneration Technology and Medical New Materials Bengbu Medical University Bengbu China

    2 shared publications
  • Ye Wenhao

    Anhui Engineering Research Center for Neural Regeneration Technology and Medical New Materials Bengbu Medical University Bengbu China

    2 shared publications

Latest Publications

  • Mechanism study of METTL3 regulating Wnt/β-Catenin signalling in Pg.LPS-stimulated hSCAPs odontogenic differentiation

    by Xiang Ge, Yongna Zhu, Yongting Ji, Lina Jiang, Xiu Ying, Min Wang, Chengxi Li, Caiyun Ma, Qingling Yang

  • Open Access

    NSUN5 as a Prognostic Biomarker Correlates with Malignant Phenotype and Therapeutic Target in Glioma

    by Ye Wenhao, Wu Huan, Zou Xiaoyun, Yang Yuanyuan, Bi Junlei, Liu Changqing, Zhao Mengyi, Zhang Yuyuan, Lu Jin, Wen Hebao, et al.

    Background: NSUN5 is a conserved RNA methyltransferase whose oncogenic role has been demonstrated in various cancers. However, its function and prognostic value in gliomas remain unclear. Methods: In this study, we systematically analyzed the expression and functional associations of NSUN5 in glioma using data from The Cancer Genome Atlas (TCGA) and the Chinese Glioma Genome Atlas (CGGA) databases. A total of 117 machine learning algorithm combinations were employed to construct and validate a prognostic model for glioma patients. In addition, in vitro experiments were performed to further validate the expression and biological functions of NSUN5. Results: NSUN5 expression is significantly upregulated in glioma and is positively associated with tumor malignancy and poor prognosis. Immune infiltration analysis revealed a marked increase in M2 macrophages in the NSUN5 high‐expression group, and NSUN5 levels were positively correlated with the expression of multiple inhibitory immune checkpoints. In addition, drug sensitivity analysis and molecular docking suggested that NSUN5 may influence the response to Olaparib. Finally, based on NSUN5‐associated genes, we constructed 117 machine learning models and identified the optimal prognostic model, STRICOM, which demonstrated robust predictive performance for patient survival. Conclusion: High NSUN5 expression is closely associated with poor prognosis in glioma patients, highlighting its potential as a prognostic biomarker and therapeutic target.

  • Open Access

    Immune Evasion Mechanism Mediated by ITPRIPL1 and Its Prognostic Implications in Glioma

    by Zou Xiaoyun, Ye Wenhao, Wu Huan, Yang Yuanyuan, Liu Changqing, Wen Hebao, Ma Caiyun

    Background: Glioma represent one of the most prevalent and lethal malignancies within the central nervous system. Recent studies have identified ITPRIPL1, a newly reported CD3ε‐inhibitory ligand, as a suppressor of T cell activation, thereby facilitating tumor immune evasion and offering a novel avenue for immunotherapeutic intervention in glioma.Methods: A comprehensive analysis was performed using datasets from The Cancer Genome Atlas (TCGA), the Chinese Glioma Genome Atlas (CGGA), and Gene Expression Omnibus (GEO). This included evaluating ITPRIPL1 expression levels in glioma, its association with clinicopathological features, prognostic significance, immune landscape, targeted drug sensitivity, and underlying biological functions. Ninety‐eight machine learning algorithm combinations were screened to identify the optimal predictive model. A nomogram was subsequently constructed and validated to assess the integrated prognostic impact of ITPRIPL1 expression on glioma patients.Results: Elevated ITPRIPL1 expression was positively correlated with higher tumor grade and poorer clinical outcomes. Immune infiltration profiling revealed that ITPRIPL1 expression was negatively associated with effector memory CD4⁺ T cells and type 17 T helper cells (Th17), but positively correlated with M2‐polarized macrophages and several immune checkpoint molecules. Moreover, drug sensitivity analyses and molecular docking studies highlighted a potential therapeutic relationship between ITPRIPL1 and antitumor agents such as AZD8055. The SuperPC model emerged as the most robust predictor and was utilized to develop a prognostic nomogram capable of reliably forecasting survival in glioma patients.Conclusions: This study reveals that ITPRIPL1 plays a dual role in glioma: It suppresses T cell–mediated immune responses, contributing to an immunosuppressive microenvironment, and interferes with the efficacy of antitumor drugs, thereby promoting tumor progression and ultimately leading to poor patient prognosis.


  • Open Access

    METTL3-m6A methylase regulates the osteo-/odontogenic potential of stem cells from apical papilla via NFIC in apical periodontitis

    by Yongna Zhu, Xiang Ge, Zhi Chen, Tingting Chen, Yue Wu, Hebao Wen, Zeyu He, Caiyun Ma